Brixton Biosciences
Cambridge
About Brixton Biosciences
Brixton Biosciences is a clinical-stage life sciences company developing novel therapies for pain treatment. Backed by deep research, the company addresses crucial unmet needs in pain management, which has historically been dominated by systemic medicine. Brixton Biosciences' innovative therapeutics, such as its novel Neural Ice™, provide pain relief in a single, safe, and easy drug-free injectable that is a non-addictive, locally targeted, and comparatively long-lasting solution.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Total funding: $35.0M
- Funding stage: Early Stage Venture
- Last round: Grant (Oct 2024)
- Website: brixtonbio.com
- Phone: +1 617-500-0213
Industries & Categories
Biotechnology, Life Science, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/brixton-biosciences-125360 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.